Practice exams / Federal law / Federal Law: Drug Regulation, Scheduling and the Supply Chain

Federal Law: Drug Regulation, Scheduling and the Supply Chain

About 12 of every 120 questions on each practice exam (Illinois MPJE, New York MPJE and Texas MPJE) come from this topic.

Sources checked

What to know

CSA schedules rest on abuse potential, medical use and dependence: Schedule I has no accepted medical use, Schedule II has high abuse potential and severe dependence, Schedule III moderate or low physical or high psychological dependence, and Schedules IV and V each a lower potential relative to the schedule above. The Attorney General schedules by rule after HHS's scientific and medical evaluation, which binds on those matters, including a recommendation not to control. Temporary Schedule I placement lasts 2 years, extendable 1 year. Examples: heroin (I); hydrocodone, methadone (II); ketamine, buprenorphine, codeine combinations up to 90 mg per unit (III); alprazolam, tramadol, carisoprodol, zolpidem (IV); pregabalin and codeine preparations up to 200 mg/100 mL (V). Insanitary conditions, failed cGMP, off-standard strength and harmful containers adulterate a drug; false labeling, missing manufacturer name, imitation and dispensing without a prescription misbrand it. New drugs need an NDA or ANDA (bioequivalent; same route, form and strength); biologics need a license. Orphan diseases affect under 200,000 people, with 7-year exclusivity. Recall classes run from I (serious harm or death) to III (harm unlikely); professionals report on MedWatch Form 3500, vaccine events to VAERS. DSCSA: dispensing on a prescription is not a transaction; suspect product rests on reason to believe, illegitimate product on credible evidence; dispensers keep transaction records 6 years. 503B facilities compound sterile drugs under pharmacist supervision. Distributors and narcotic treatment programs register with DEA for 1 year, and inspections exclude pricing and financial data without written consent.

Where it comes from

  • 21 U.S.C. 811
  • 21 U.S.C. 812
  • 21 CFR 1308.11-1308.15
  • 21 U.S.C. 351
  • 21 U.S.C. 352
  • 21 U.S.C. 353
  • 21 U.S.C. 353b
  • 21 U.S.C. 355
  • 42 U.S.C. 262
  • 21 U.S.C. 360bb
  • 21 U.S.C. 360cc
  • 21 CFR 7.3
  • 21 CFR 7.42
  • 42 U.S.C. 300aa-25
  • 21 U.S.C. 360eee
  • 21 U.S.C. 360eee-1
  • 21 CFR 1301.13
  • 21 U.S.C. 880
  • 21 CFR 1316.06

Try a practice question

Under the Controlled Substances Act, 21 U.S.C. 812(b), which finding is required to place a drug or other substance in Schedule I?

  1. AA currently accepted medical use with severe restrictions in treatment
  2. BA low potential for abuse relative to Schedule IV substances
  3. CAbuse that may lead to moderate or low physical dependence
  4. DNo currently accepted medical use in treatment in the United States
Show the answer

No currently accepted medical use in treatment in the United States. Schedule I requires a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety under medical supervision.

21 U.S.C. 812(b)(1)

Practice exams that test this topic

Not sure which exam you take? See Pharmacy Law Exam (MPJE) Requirements.